MONTREAL (CANADA) – October 25, 2021 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has appointed Michael D. Harvey, PhD as Chief Development Officer (CDO), effective immediately. With over 20 years of experience and a proven track record in the pharmaceutical and biotechnology industry, Dr. Harvey will now oversee all nonclinical operations at Inversago, as well as global regulatory affairs, pharmaceutical development, and discovery research programs.
Dr. Michael Harvey joined Inversago in October 2020 as senior Vice-President, Drug Development. Click here to access the press release relative to his arrival at Inversago.
About Inversago Pharma
Headquartered in Montreal, Inversago Pharma is a clinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Prader-Willi Syndrome (PWS), non-alcoholic steatohepatitis (NASH), type 1 diabetes (T1D) and diabetic nephropathy.
– 30 –
Contact:
François Ravenelle, PhD
Chief Executive Officer
Inversago Pharma inc.
info@inversago.com
